BibTex RIS Cite
Year 2015, Volume: 32 Issue: 4, 421 - 425, 01.10.2015

Abstract

References

  • 1. Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996;334:494-500. [CrossRef]
  • 2. Ito Y, Arahata Y, Goto Y, Hirayama M, Nagamutsu M, Yasuda T, et al. Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome. AJNR Am J Neuroradiol 1998;19:415-7.
  • 3. Edwards MJ, Walker R, Vinnicombe S, Barlow C, MacCallum P, Foran JM. Reversible posterior leukoencephalopathy syndrome following CHOP chemotherapy for diffuse large B-cell lymphoma. Ann Oncol 2001;12:1327-9. [CrossRef]
  • 4. Tam CS, Galanos J, Seymour JF, Pitman AG, Stark RJ, Prince HM. Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignancies. Am J Hematol 2004;77:72-6. [CrossRef]
  • 5. Rajasekhar A, George TJ Jr. Gemcitabine-induced reversible posterior leukoencephalopathy syndrome: A case report and review of literature. Oncologist 2007;12:1332-5. [CrossRef
  • 6. Bhatt A, Farooq MU, Bhatt S, Majid A, Kassab MY. Periodic lateralized epielptiform discharges: an initial electrographic pattern in reversible posterior leukoencephalopathy syndrome. Neurol Neurochir Pol 2008;42:55-9.
  • 7. Fugate JE, Claassen DO, Cloft HJ, Kallmes DF, Kozak OS, Rabinstein AA. Posterior reversible encephalopathy syndrome: associated clinical and radiological findings. Mayo Clin Proc 2010;85:427-32. [CrossRef]
  • 8. Imai H, Okuno N, Ishihara S, Nakano S, Higuchi S, Arai T, et al. Reversible posterior leukoencephalopathy syndrome after carboplatin and paclitaxel regimen for lung cancer. Intern Med 2012;51:911-5. [CrossRef]
  • 9. Vieillot S, Pouessel D, de Champfleur NM, Becht C, Culine S. Reversible posterior leukoencephalopathy syndrome after carboplatin therapy. Ann Oncol 2007;18:608-9. [CrossRef]
  • 10. Kozak OS, Wijdicks EF, Manno EM, Miley JT, Rabinstein AA. Status epilepticus as initial manifestation of posterior reversible encephalopathy syndrome. Neurology 2007;69:894-7. [CrossRef]
  • 11. Skiba V, Etienne M, Miller JA. Development of chronic epilepsy after recurrent episodes of posterior reversible leukoencephalopathy syndrome associated with periodic lateralized epileptiform discharges. Seizure 2011;20:93-5. [CrossRef]
  • 12. Newton HB. Neurological complications of chemotherapy to the central nervous system. Handb Clin Neurol 2012;105:903- 16. [CrossRef]
  • 13. Sharief U, Perry DJ. Delayed reversible posterior encephalopathy syndrome following chemotherapy with oxaliplatin. Clin Colorectal Cancer 2009;8:163-5. [CrossRef]
  • 14. Gorman DJ, Kefford R, Stuart-Harris R. Focal encephalopathy after cisplatin therapy. Med J Aust 1989;150:399-401.
  • 15. Onujiogu N, Lengyel E, Yamada SD. Reversible posterior leukoencephalopathy syndrome following intravenous paclitaxel and intraperitoneal cisplatin chemotherapy for fallopian tube cancer. Gynecol Oncol 2008;111:537-9. [CrossRef]
  • 16. Bartynski WS. Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features. AJNR Am J Neuroradiol 2008;29:1036-42.[CrossRef]

Reversible Posterior Leukoencephalopathy Syndrome Due to Carboplatin and Paclitaxel Therapy

Year 2015, Volume: 32 Issue: 4, 421 - 425, 01.10.2015

Abstract

Background: Reversible posterior leukoencephalopathy syndrome (RPLS) is a clinicoradiologic syndrome characterized by headache, decreased alertness, seizures, visual abnormalities, and white matter changes indicative of cerebral edema. Although the pathogenesis remains poorly understood, several etiological causes have been described. RPLS is a common complication of chemotherapeutics because of its toxic effect on the central nervous system. This syndrome is frequently associated with seizures but rarely seen with status epilepticus and periodic lateralized epileptiform discharges (PLEDs). Case Report: We present a case with metastatic lung cancer that developed RPLS after carboplatin and paclitaxel therapy. Our case was admitted to the hospital with status epilepticus and her electroencephalography showed PLEDs. Conclusion: It is important to closely monitor blood pressure and electrolyte levels in patients who take chemotherapeutic agents, especially when there is no previous history of hypertension. It should be kept in mind that RPLS is a causative factor of status epilepticus and PLEDs.

References

  • 1. Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996;334:494-500. [CrossRef]
  • 2. Ito Y, Arahata Y, Goto Y, Hirayama M, Nagamutsu M, Yasuda T, et al. Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome. AJNR Am J Neuroradiol 1998;19:415-7.
  • 3. Edwards MJ, Walker R, Vinnicombe S, Barlow C, MacCallum P, Foran JM. Reversible posterior leukoencephalopathy syndrome following CHOP chemotherapy for diffuse large B-cell lymphoma. Ann Oncol 2001;12:1327-9. [CrossRef]
  • 4. Tam CS, Galanos J, Seymour JF, Pitman AG, Stark RJ, Prince HM. Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignancies. Am J Hematol 2004;77:72-6. [CrossRef]
  • 5. Rajasekhar A, George TJ Jr. Gemcitabine-induced reversible posterior leukoencephalopathy syndrome: A case report and review of literature. Oncologist 2007;12:1332-5. [CrossRef
  • 6. Bhatt A, Farooq MU, Bhatt S, Majid A, Kassab MY. Periodic lateralized epielptiform discharges: an initial electrographic pattern in reversible posterior leukoencephalopathy syndrome. Neurol Neurochir Pol 2008;42:55-9.
  • 7. Fugate JE, Claassen DO, Cloft HJ, Kallmes DF, Kozak OS, Rabinstein AA. Posterior reversible encephalopathy syndrome: associated clinical and radiological findings. Mayo Clin Proc 2010;85:427-32. [CrossRef]
  • 8. Imai H, Okuno N, Ishihara S, Nakano S, Higuchi S, Arai T, et al. Reversible posterior leukoencephalopathy syndrome after carboplatin and paclitaxel regimen for lung cancer. Intern Med 2012;51:911-5. [CrossRef]
  • 9. Vieillot S, Pouessel D, de Champfleur NM, Becht C, Culine S. Reversible posterior leukoencephalopathy syndrome after carboplatin therapy. Ann Oncol 2007;18:608-9. [CrossRef]
  • 10. Kozak OS, Wijdicks EF, Manno EM, Miley JT, Rabinstein AA. Status epilepticus as initial manifestation of posterior reversible encephalopathy syndrome. Neurology 2007;69:894-7. [CrossRef]
  • 11. Skiba V, Etienne M, Miller JA. Development of chronic epilepsy after recurrent episodes of posterior reversible leukoencephalopathy syndrome associated with periodic lateralized epileptiform discharges. Seizure 2011;20:93-5. [CrossRef]
  • 12. Newton HB. Neurological complications of chemotherapy to the central nervous system. Handb Clin Neurol 2012;105:903- 16. [CrossRef]
  • 13. Sharief U, Perry DJ. Delayed reversible posterior encephalopathy syndrome following chemotherapy with oxaliplatin. Clin Colorectal Cancer 2009;8:163-5. [CrossRef]
  • 14. Gorman DJ, Kefford R, Stuart-Harris R. Focal encephalopathy after cisplatin therapy. Med J Aust 1989;150:399-401.
  • 15. Onujiogu N, Lengyel E, Yamada SD. Reversible posterior leukoencephalopathy syndrome following intravenous paclitaxel and intraperitoneal cisplatin chemotherapy for fallopian tube cancer. Gynecol Oncol 2008;111:537-9. [CrossRef]
  • 16. Bartynski WS. Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features. AJNR Am J Neuroradiol 2008;29:1036-42.[CrossRef]
There are 16 citations in total.

Details

Other ID JA86GE38UT
Journal Section Research Article
Authors

Melek Kandemir This is me

Belgin Küçükkaya This is me

Muzaffer Savaş Tepe This is me

Zehra Betül Yalçıner This is me

Nedret Taflan Salepçi This is me

Publication Date October 1, 2015
Published in Issue Year 2015 Volume: 32 Issue: 4

Cite

APA Kandemir, M., Küçükkaya, B., Tepe, M. S., Yalçıner, Z. B., et al. (2015). Reversible Posterior Leukoencephalopathy Syndrome Due to Carboplatin and Paclitaxel Therapy. Balkan Medical Journal, 32(4), 421-425.
AMA Kandemir M, Küçükkaya B, Tepe MS, Yalçıner ZB, Salepçi NT. Reversible Posterior Leukoencephalopathy Syndrome Due to Carboplatin and Paclitaxel Therapy. Balkan Medical Journal. October 2015;32(4):421-425.
Chicago Kandemir, Melek, Belgin Küçükkaya, Muzaffer Savaş Tepe, Zehra Betül Yalçıner, and Nedret Taflan Salepçi. “Reversible Posterior Leukoencephalopathy Syndrome Due to Carboplatin and Paclitaxel Therapy”. Balkan Medical Journal 32, no. 4 (October 2015): 421-25.
EndNote Kandemir M, Küçükkaya B, Tepe MS, Yalçıner ZB, Salepçi NT (October 1, 2015) Reversible Posterior Leukoencephalopathy Syndrome Due to Carboplatin and Paclitaxel Therapy. Balkan Medical Journal 32 4 421–425.
IEEE M. Kandemir, B. Küçükkaya, M. S. Tepe, Z. B. Yalçıner, and N. T. Salepçi, “Reversible Posterior Leukoencephalopathy Syndrome Due to Carboplatin and Paclitaxel Therapy”, Balkan Medical Journal, vol. 32, no. 4, pp. 421–425, 2015.
ISNAD Kandemir, Melek et al. “Reversible Posterior Leukoencephalopathy Syndrome Due to Carboplatin and Paclitaxel Therapy”. Balkan Medical Journal 32/4 (October 2015), 421-425.
JAMA Kandemir M, Küçükkaya B, Tepe MS, Yalçıner ZB, Salepçi NT. Reversible Posterior Leukoencephalopathy Syndrome Due to Carboplatin and Paclitaxel Therapy. Balkan Medical Journal. 2015;32:421–425.
MLA Kandemir, Melek et al. “Reversible Posterior Leukoencephalopathy Syndrome Due to Carboplatin and Paclitaxel Therapy”. Balkan Medical Journal, vol. 32, no. 4, 2015, pp. 421-5.
Vancouver Kandemir M, Küçükkaya B, Tepe MS, Yalçıner ZB, Salepçi NT. Reversible Posterior Leukoencephalopathy Syndrome Due to Carboplatin and Paclitaxel Therapy. Balkan Medical Journal. 2015;32(4):421-5.